Period: Jan 8, 2015 to Mar 26, 2016
Lead Plaintiff Deadline: May 23, 2017
Summary of Case:
A securities class action has been filed against OvaScience, Inc. (OVAS) on behalf of all purchasers of common stock of OvaScience between Jan 8, 2015 through Mar 26, 2015. This case has been filed in the USDC - Massachusetts.
The Complaint alleges as follows: Throughout the Class Period, defendants issued false and misleading statements and/or failed to disclose material adverse facts about the Company's business, operations and prospects. In particular, defendants caused the Company to issue false and misleading statements and/or failed to disclose, among other things, that: (1) the science behind AUGMENT had not been scientifically validated; (2) the Company was unable to achieve the purported success rates it claimed; (3) the reasons why the Company moved its studies outside of the United States; and (4) that at all relevant times, the Company's profitability and prospects were false and misleading.
As such, during the class period, defendants failed to disclose that the approximately 150 patients that had received OvaScience's AUGMENT procedure in 2014 did not achieve a pregnancy success rate that was significantly higher than the rate achieved without the Company's AUGMENT procedure. As a result of the false and misleading statements issued by defendants, the price of the Company's shares was artificially inflated throughout the Class Period. The Company's shares currently trade at under $2.00 per share and have since December 2016.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.